{"title": "HAVRIX Vaccine | Hepatitis A Immunization | GSKPro for HCPs", "author": null, "url": "https://gskpro.com/en-us/products/havrix/", "hostname": "gskpro.com", "description": "Visit the GSKPro site to learn about Hepatitis A vaccine. See prescribing info & details for HCPs.", "sitename": "gskpro.com", "date": "2020-03-02", "cleaned_text": "4 HAVRIX is a vaccine indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV. Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or to any component of HAVRIX, including neomycin, is a contraindication to administration of HAVRIX. Important Safety Information for HAVRIX - Severe allergic reaction (eg, anaphylaxis) after a previous dose of any hepatitis A-containing vaccine, or to any component of HAVRIX, including neomycin, is a contraindication to administration of HAVRIX - The tip caps of the prefilled syringes for HAVRIX contain natural rubber latex, which may cause allergic reactions - Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope - Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to HAVRIX - In clinical trials with HAVRIX in children 11 to 25 months of age, the most common solicited adverse reactions were injection-site pain and redness, irritability, drowsiness, and loss of appetite - In clinical trials with HAVRIX in adults and children 2 years of age and older, the most common solicited adverse reactions were injection-site soreness and headache - Vaccination with HAVRIX may not result in protection in all vaccine recipients "}